Shares of Eloxx Pharmaceuticals, Inc. (ELOX), a clinical-stage biopharmaceutical company developing small-molecule therapies for genetic diseases caused by nonsense mutations, fell over 31% after the company announced the pricing of a $66 million public offering and its uplisting to the Nasdaq Capital Market.
Seaport Therapeutics, Inc. (SPTX), reported a wider net loss for its first financial quarter ended March 31, 2026, and provided near term milestone update. Company Profile Seaport Therapeutics is a clinical-stage therapeutics company focused on development of new medicines to address patients...
GSK plc (GSK) has entered into an agreement to acquire Nuvalent, Inc (NUVL), a Boston-based clinical-stage biopharmaceutical company developing targeted cancer therapies, in a transaction valued at $10.6 billion (£8.0 billion). The deal strengthens GSK's oncology pipeline with late-stage assets aimed at non-small cell lung cancer.
IDEAYA Biosciences, Inc. (IDYA), a clinical-stage oncology company, announced the pricing of an underwritten public offering of 5.56 million shares at an offering price of $27.00 per share and pre-funded warrants to purchase up to 5.56 million shares at an offering price of $26.9999 per pre-funded warrant....
Today's top gainers include Tango Therapeutics, following encouraging pancreatic cancer trial data; Aspire Biopharma, ahead of upcoming milestones; Alvotech, after FDA acceptance of its interchangeable biosimilar to Entyvio for review; and Zevra Therapeutics, on actions strengthening exclusivity for MIPLYFFA, among others.
Alvotech (ALVO), a biotechnology company, announced that its Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) for intravenous administration, has been accepted for review by the FDA. According to the company, the Biologics License Application...
CorMedix Therapeutics (CRMD) announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling in favour of its subsidiary Melinta Therapeutics, upholding the validity of patents covering MINOCIN for Injection and confirming infringement by Nexus Pharmaceuticals proposed generic product.
Ionis Pharmaceuticals, Inc. (IONS), a commercial-stage biotechnology company, announced the appointment of Ludwig Hantson as a Board of Director, effective immediately. Hantson brings more than 30 years of leadership experience from biopharmaceutical and medical device companies. He served as the...
Marvel Biosciences Corp. (MBCOF), a biotechnology company developing therapeutics for treatments for neurological diseases and neurodevelopmental disorders, announced that the Australian patent application for its lead investigational therapeutic, MB-204, for autistic disorder was accepted and that the...
Vor Bio (VOR) today announced that Telitacicept (developed by RemeGen) has received approval from China's NMPA for the treatment of adult patients with Sjögren's disease.
Teva Pharmaceutical Industries Limited (TEVA), a pharmaceuticals company, on Friday announced new IMPACT-TD and RIM-TD data evaluating AUSTEDO and AUSTEDO XR in treating Tardive dyskinesia. The data was presented at the Psych Congress Elevate conference. Tardive dyskinesia (TD) is a debilitating,...
Galmed Pharmaceuticals Ltd. (GLMD) fell more than 16% after the company announced a definitive agreement to acquire Colospan Ltd., a commercial-stage medical device company focused on colorectal surgery.
BioCardia Inc. (BCDA), a clinical-stage regenerative medicine company, on Monday announced closing financing worth $4 million dollars. The company sold 3,509,604 shares at an average price of $1.279 per share on June 5, 2026. The proceeds of the financing were $4.4 million. The net proceeds are...
Shares of GoHealth, Inc. (GOCO) slipped 36% after the company announced a voluntary, prepackaged Chapter 11 process designed to strengthen its financial position before the 2026 Medicare Annual Enrollment Period (AEP).
Sanofi (SNY) announced that the European Commission has granted clearance for Sarclisa (isatuximab) subcutaneous (SC) in combination with standard-of-care (SOC) regimens across all existing indications for Sarclisa intravenous (IV) formulation. Like Sarclisa IV, Sarclisa subcutaneous is also approved...
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.